Should the human microbiome be considered when developing vaccines?
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Rosana B R
RB
Ferreira
L Caetano M
LC
Antunes
B Brett
BB
Finlay
D001424:Bacterial Infections / Q000235:genetics* / Q000276:immunology / Q000517:prevention & control*; D015195:Drug Design; D006801:Humans; D054892:Metagenome; D014612:Vaccines / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use*
D014612:Vaccines